Cargando…
A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal c...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207470/ https://www.ncbi.nlm.nih.gov/pubmed/34169195 http://dx.doi.org/10.1016/j.ekir.2021.02.036 |
_version_ | 1783708783627730944 |
---|---|
author | March, Daniel S. Hurt, Adam W. Grantham, Charlotte E. Churchward, Darren R. Young, Hannah M.L. Highton, Patrick J. Dungey, Maurice Bishop, Nicolette C. Smith, Alice C. Graham-Brown, Matthew P.M. Cooper, Nicola J. Burton, James O. |
author_facet | March, Daniel S. Hurt, Adam W. Grantham, Charlotte E. Churchward, Darren R. Young, Hannah M.L. Highton, Patrick J. Dungey, Maurice Bishop, Nicolette C. Smith, Alice C. Graham-Brown, Matthew P.M. Cooper, Nicola J. Burton, James O. |
author_sort | March, Daniel S. |
collection | PubMed |
description | INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal cost-effectiveness analysis of adult participants with end-stage kidney disease undertaking in-center maintenance hemodialysis enrolled in the CYCLE-HD trial. Data on hospital utilization, primary care consultations, and prescribed medications were extracted from medical records for the 6 months before, during, and after a 6-month program of thrice-weekly IDC. The cost-effectiveness analysis was conducted from a health care service perspective and included the cost of implementing the IDC intervention. The base-case analyses included a 6-month “within trial” analysis and a 12-month “within and posttrial” analysis considering health care utilization and quality of life (QoL) outcomes. RESULTS: Data from the base-case within trial analysis, based on 109 participants (n = 56 control subjects and n = 53 IDC subjects) showed a reduction in health care utilization costs between groups, favoring the IDC group, and a 73% chance of IDC being cost-effective compared with control subjects at a willingness to pay of £20,000 and £30,000 per quality-adjusted life year (QALY) gained. When QoL data points were extrapolated forward to 12 months, the probability of IDC being cost-effective was 93% and 94% at £20,000 and £30,000 per QALY gained. Sensitivity analysis broadly confirms these findings. CONCLUSION: A 6-month program of IDC is cost-effective and the implementation of these programs nationally should be a priority. |
format | Online Article Text |
id | pubmed-8207470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82074702021-06-23 A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial March, Daniel S. Hurt, Adam W. Grantham, Charlotte E. Churchward, Darren R. Young, Hannah M.L. Highton, Patrick J. Dungey, Maurice Bishop, Nicolette C. Smith, Alice C. Graham-Brown, Matthew P.M. Cooper, Nicola J. Burton, James O. Kidney Int Rep Clinical Research INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal cost-effectiveness analysis of adult participants with end-stage kidney disease undertaking in-center maintenance hemodialysis enrolled in the CYCLE-HD trial. Data on hospital utilization, primary care consultations, and prescribed medications were extracted from medical records for the 6 months before, during, and after a 6-month program of thrice-weekly IDC. The cost-effectiveness analysis was conducted from a health care service perspective and included the cost of implementing the IDC intervention. The base-case analyses included a 6-month “within trial” analysis and a 12-month “within and posttrial” analysis considering health care utilization and quality of life (QoL) outcomes. RESULTS: Data from the base-case within trial analysis, based on 109 participants (n = 56 control subjects and n = 53 IDC subjects) showed a reduction in health care utilization costs between groups, favoring the IDC group, and a 73% chance of IDC being cost-effective compared with control subjects at a willingness to pay of £20,000 and £30,000 per quality-adjusted life year (QALY) gained. When QoL data points were extrapolated forward to 12 months, the probability of IDC being cost-effective was 93% and 94% at £20,000 and £30,000 per QALY gained. Sensitivity analysis broadly confirms these findings. CONCLUSION: A 6-month program of IDC is cost-effective and the implementation of these programs nationally should be a priority. Elsevier 2021-04-08 /pmc/articles/PMC8207470/ /pubmed/34169195 http://dx.doi.org/10.1016/j.ekir.2021.02.036 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research March, Daniel S. Hurt, Adam W. Grantham, Charlotte E. Churchward, Darren R. Young, Hannah M.L. Highton, Patrick J. Dungey, Maurice Bishop, Nicolette C. Smith, Alice C. Graham-Brown, Matthew P.M. Cooper, Nicola J. Burton, James O. A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title | A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title_full | A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title_fullStr | A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title_full_unstemmed | A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title_short | A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial |
title_sort | cost-effective analysis of the cycle-hd randomized controlled trial |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207470/ https://www.ncbi.nlm.nih.gov/pubmed/34169195 http://dx.doi.org/10.1016/j.ekir.2021.02.036 |
work_keys_str_mv | AT marchdaniels acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT hurtadamw acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT granthamcharlottee acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT churchwarddarrenr acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT younghannahml acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT hightonpatrickj acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT dungeymaurice acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT bishopnicolettec acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT smithalicec acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT grahambrownmatthewpm acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT coopernicolaj acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT burtonjameso acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT marchdaniels costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT hurtadamw costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT granthamcharlottee costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT churchwarddarrenr costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT younghannahml costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT hightonpatrickj costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT dungeymaurice costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT bishopnicolettec costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT smithalicec costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT grahambrownmatthewpm costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT coopernicolaj costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial AT burtonjameso costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial |